JP2023513605A - がんを処置するためのスプライシング由来抗原を含む組成物および方法 - Google Patents

がんを処置するためのスプライシング由来抗原を含む組成物および方法 Download PDF

Info

Publication number
JP2023513605A
JP2023513605A JP2022549103A JP2022549103A JP2023513605A JP 2023513605 A JP2023513605 A JP 2023513605A JP 2022549103 A JP2022549103 A JP 2022549103A JP 2022549103 A JP2022549103 A JP 2022549103A JP 2023513605 A JP2023513605 A JP 2023513605A
Authority
JP
Japan
Prior art keywords
peptide
cells
cell
cancer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549103A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021163562A5 (https=
JP2023513605A5 (https=
Inventor
イ シン
オーウェン ウィッテ
ジョン フィリップス
ヤン パン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2023513605A publication Critical patent/JP2023513605A/ja
Publication of JPWO2021163562A5 publication Critical patent/JPWO2021163562A5/ja
Publication of JP2023513605A5 publication Critical patent/JP2023513605A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022549103A 2020-02-14 2021-02-12 がんを処置するためのスプライシング由来抗原を含む組成物および方法 Pending JP2023513605A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976654P 2020-02-14 2020-02-14
US62/976,654 2020-02-14
PCT/US2021/017958 WO2021163562A2 (en) 2020-02-14 2021-02-12 Compositions and methods comprising splicing-derived antigens for treating cancer

Publications (3)

Publication Number Publication Date
JP2023513605A true JP2023513605A (ja) 2023-03-31
JPWO2021163562A5 JPWO2021163562A5 (https=) 2024-02-16
JP2023513605A5 JP2023513605A5 (https=) 2024-02-16

Family

ID=77295208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549103A Pending JP2023513605A (ja) 2020-02-14 2021-02-12 がんを処置するためのスプライシング由来抗原を含む組成物および方法

Country Status (5)

Country Link
US (1) US20240182518A1 (https=)
EP (1) EP4103738A4 (https=)
JP (1) JP2023513605A (https=)
CN (1) CN115485395A (https=)
WO (1) WO2021163562A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4055182A4 (en) * 2019-11-08 2024-07-03 The Regents Of The University Of California IDENTIFICATION OF SPLICE-DRIVEN ANTIGENS FOR CANCER TREATMENT
US20250352576A1 (en) * 2022-04-01 2025-11-20 The Regents Of The University Of California Methods and compositions for treating gliomas
CN116178567B (zh) * 2022-10-28 2025-01-28 四川大学华西医院 一种靶向TGFβRII的嵌合抗原受体及其用途
EP4695284A1 (en) * 2023-04-11 2026-02-18 The Regents of University of California Human t cell receptors targeting tumor-enhanced splicing epitopes on hla-a*02:01 for small cell carcinoma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
JP2019513005A (ja) * 2016-02-19 2019-05-23 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US20180305776A1 (en) * 2017-04-20 2018-10-25 The Board Of Trustees Of The Leland Stanford Junior University Myc-reporters, cells containing myc-reporters and methods of use thereof
EP4055182A4 (en) * 2019-11-08 2024-07-03 The Regents Of The University Of California IDENTIFICATION OF SPLICE-DRIVEN ANTIGENS FOR CANCER TREATMENT

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
JP2019513005A (ja) * 2016-02-19 2019-05-23 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOINFORMATICS, vol. 30, no. 2, JPN6025004857, 2014, pages 151 - 156, ISSN: 0005523347 *
CANCER CELL, vol. 34, JPN6025004856, 2018, pages 211 - 224, ISSN: 0005523348 *
DATABASE GENBANK, ACCESSION NO. AY573302, [ONLINE], JPN6025004859, 21 September 2004 (2004-09-21), pages 2025 - 1, ISSN: 0005671823 *
DATABASE GENBANK, ACCESSION NO. AY573303, [ONLINE], JPN6025004858, 21 September 2004 (2004-09-21), pages 2025 - 1, ISSN: 0005671824 *
FEBS LETTERS, vol. 574, JPN6025004861, 2004, pages 13 - 19, ISSN: 0005671822 *

Also Published As

Publication number Publication date
WO2021163562A2 (en) 2021-08-19
EP4103738A4 (en) 2024-05-29
EP4103738A2 (en) 2022-12-21
US20240182518A1 (en) 2024-06-06
WO2021163562A3 (en) 2021-10-28
CN115485395A (zh) 2022-12-16

Similar Documents

Publication Publication Date Title
US20240076372A1 (en) Car t cell therapies with enhanced efficacy
JP7524249B2 (ja) 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
US11999794B2 (en) Human mesothelin chimeric antigen receptors and uses thereof
TWI890660B (zh) Bcma 嵌合抗原受體及其用途
JP6736540B2 (ja) Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
US20210396739A1 (en) Biomarkers for evaluating car-t cells to predict clinical outcome
US10479997B2 (en) Compositions and methods for diagnosis and treatment of prostate cancer
KR20220104217A (ko) Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
JP2021526814A5 (https=)
JP2022554395A (ja) がんを処置するためのスプライシング由来抗原の同定
JP2023513605A (ja) がんを処置するためのスプライシング由来抗原を含む組成物および方法
WO2018013918A2 (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
JP2023549504A (ja) キメラ抗原受容体（ｃａｒ）発現細胞との組合せ療法
JP2017510257A (ja) Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ）
JPWO2019241426A5 (https=)
WO2016038550A1 (en) Inhibition of prmt5 to treat mtap-deficiency-related diseases
US20250146076A1 (en) Alk gene fusions and uses thereof
JP2023544199A (ja) 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
US20250049848A1 (en) Methods and compositions for altering a tumor microbiome
WO2025050009A2 (en) Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
HK40092056A (zh) 用於治疗癌症的剪接衍生抗原的鉴定
BR122023022573A2 (pt) Moléculas de ácido nucleico isoladas, receptores de antígeno quimérico de bcma e usos dos mesmos, moléculas de polipeptídeo isoladas, domínios de ligação anti-bcma, vetores, células e métodos de produção das mesmas
BR112020025048B1 (pt) Moléculas de ácido nucleico isoladas, receptores de antígeno quiméricos de bcma, usos dos mesmos, vetor, e métodos de produção de uma célula

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221019

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250826